Condition: Radiation Toxicity · Chemotherapeutic Toxicity · Chemotherapy-induced Peripheral Neuropathy · Sponsor: Bernardino Clavo, MD, PhD
The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between June-2022 and December-2025
This description comes directly from the study's public registry record.
Bernardino Clavo, MD, PhyD · (34)928449278 · bernardinoclavo@gmail.com
Francisco Rodríguez-Esparragón, BSci, PhyD · (34)928449288 · afrodesp@gmail.com
Always discuss trial participation with your own doctor first.
| Dr. Negrín University Hospital | Las Palmas, Las Palmas, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05417737